Zamaporvint (RXC004)是一种口服活性的选择性Wnt抑制剂，通过靶向Porcupine抑制Wnt配体的棕榈酰化、分泌及通路激活。它在依赖Wnt的肿瘤模型中显示出强效抗增殖活性与良好的药代动力学特征，具备多机制抗肿瘤潜力。

[1] Phillips C, Bhamra I, Eagle C, Flanagan E, Armer R, Jones CD, Bingham M, Calcraft P, Edmenson Cook A, Thompson B, Woodcock SA. The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent Cancer Models. Cancer Res Commun. 2022 Sep 2;2(9):914-928. doi: 10.1158/2767-9764.CRC-21-0095. PMID: 36922934; PMCID: PMC10010340.